SCOTTSDALE, AZ USA (UroToday.com) - This was a review of a prospective database of non-neurogenic women who underwent Macroplastique® (MPQ) injection for SUI due to intrinsic sphincter deficiency. The authors’ objective was to examine if initial postoperative urinary retention after transurethral injection of the bulking agent MPQ, for women with stress urinary incontinence (SUI), is a predictor of success.
Postoperative retention was defined as an inability to void after injection, requiring a catheter for 24–48 hours, or difficulty voiding immediately postoperatively (post void residual > 200 ml by bladder scan). Women excluded were those on self-catheterization, with a suprapubic tube, those who had a concomitant procedure, or with follow up < 6 months.
The definition of success was patient self-report of sufficient continence for not desiring any additional therapy (e.g., dry or with rare leakage.)
Patients were divided into 2 groups:
- Group 1: Retention post-operatively (n=16)
- Group 2: No retention postoperatively.(n=36)
Fifty-two of 92 women met all inclusion criteria. Success was 81% for group 1 (13/16) vs 15/36 (42%) in group 2 (p < 0.01). In group 1, 3 women underwent repeat injection (1) and fascial sling (2), whereas in group 2, 13 patients underwent repeat injections (9), fascial sling (3) or artificial urinary sphincter (1).
The authors concluded that postoperative transient retention was seen in nearly one-third of women immediately after MPQ injection; these women remained dry or were markedly improved, and did not desire additional SUI therapy.
Presented by H. Aggarwal and P. Zimmern at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Winter Meeting - February 24 - 28, 2015 - JW Marriott Camelback Inn Resort & Spa - Scottsdale, AZ USA
Reported by Diane K. Newman, DNP, FAAN, BCB-PMD, medical writer for UroToday.com.